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Diabetes mellitus is a metabolic syndrome characterized by an increase in the blood glucose level. Treatment of diabetes is
complicated due to multifactorial nature of the disease. Azadirachta indica Adr. Juss and Bougainvillea spectabilis are reported
to have medicinal values including antidiabetic properties. In the present study using in vivo diabetic murine model, A. indica
and B. spectabilis chloroform, methanolic and aqueous extracts were investigated for the biochemical parameters important for
controlling diabetes. It was found that A. indica chloroform extract and B. spectabilis aqueous, methanolic extracts showed a
good oral glucose tolerance and signiﬁcantly reduced the intestinal glucosidase activity. Interestingly, A. indica chloroform and B.
spectabilis aqueous extracts showedsigniﬁcantincreaseinglucose-6-phosphatedehydrogenase activity andhepatic, skeletalmuscle
glycogen content after 21 days of treatment. In immunohistochemical analysis, we observed a regeneration of insulin-producing
cells and corresponding increase in the plasma insulin and c-peptide levels with the treatment of A. indica chloroform and B.
spectabilis aqueous, methanolic extracts. Analyzing the results, it is clear that A. indica chloroform and B. spectabilis aqueous
extracts are good candidates for developing new neutraceuticals treatment for diabetes.
1.Introduction
Diabetes is a chronic disorder aﬀecting the population on
epidemic level. Diabetes results from abnormal metabolism
of insulin wherein insulin action is impaired, or absolute
insulin deﬁciencyresultsin imbalance ofglucosemetabolism
and leads to a syndrome called diabetes mellitus [1, 2].
In the present study using in vivo streptozotocin (STZ)-
induced diabetic murine model, we investigated the antidi-
abetic properties of diﬀerent extracts of A. indica and B.
spectabilis and tested biochemical parameters such as fasting
glucoselevel, glucosidase activity, G6PD activity, hepatic and
skeletal glycogen stores and restoration of functional β-cell
mass for possible biological action.
Many oral antidiabetic drugs used today fail to give a
long-term glycemic control [3, 4]. The herbal extracts which
are eﬀective in lowering blood glucose level with minimal
or no side eﬀects are known to be used as antidiabetic
remedies [5, 6]. Many compounds isolated from these plants
are used in combinational therapy for diabetes [7–12].
Herbal extracts from Tamarindus indica, Ceilba pentandra,
Syzygium cuminii and Trigonella foenum are known for
their hypoglycemic eﬀects [13–15]. Azadirachta indica Adr.
Juss. is known to possess hypolipidemic, hypoglycemic,
immunostimulant and hepatoprotective properties [16, 17].
While nimbocinone, nimolinone, kulactone, nimocinolides,
isonimocinolide, nimbin, salanin, azadirachtin, ﬂavonoids,
myricetin, meldenindiol, vilasinin, margosinolide, isomar-
gosinolide, desacetyldihydronimbic acid have been isolated
from A. indica leaves having medicinal properties [18–
21], Bougainvillea spectabilis leaves contain d-pinitol (3-
O-methylchiroinositol) and is claimed to exert insulin-like
eﬀect [22–24]. We have earlier conﬁrmed the glucosidase
inhibitory activity of A. indica and B. spectabilis against
murine pancreatic andintestinal glucosidase[25],suggesting
oneoftheimportant underlying mechanisms ofantidiabeto-
genic activity.
There are reports showing plant extracts exerting ben-
eﬁcial eﬀects in the diabetic environment by improving
and/or mimicking insulin action [26, 27]. They are also
thought to enhance insulin secretion in streptozotocin-
induced diabetic mice [7, 28]. The insulin deﬁciency causes2 Evidence-Based Complementary and Alternative Medicine
changes in glucose metabolism and biochemical processes,
thereby increasing fasting glucose level, decreasing hepatic
and skeletal glycogen content and decreasing glucose-6-
phosphate dehydrogenase (G6PD) activity. Reduction in
G6PD activity lowers the intracellular NADPH level that
causes oxidative stress, a critical underlying mechanism in
diabetes [29]. During prolonged diabetic condition, insulin
resistance results in the depletion of glycogen stores in
liver and tissue muscles which leads to hyperglycemia and
weight loss [30]. One of the common complications seen
in diabetic patients is postprandial hyperglycemia (PPHG),
and therapeutic approaches for decreasing PPHG is to retard
absorption of glucose by the inhibition of carbohydrate-
hydrolyzing enzymes, namely, glucosidases [31, 32] Figure 7.
2.Materialsand Methods
2.1. Plant Material. The leaves of A. indica (herbarium no
MBBP 5) and B. spectabilis (herbarium no MBBP 1) were
collected from the Western Ghats in and around Pune city
in the months of May and June, and were authenticated by
the Botanical SurveyofIndia (BSI),Pune. The plant material
was sequentially extracted through a soxhlet extractor using
methanol, chloroform and distilled water [25].
2.2.ToxicityBioassay. Thetoxicitytestofextractswascarried
out on brine shrimp, Artemia salina [33]. Brine shrimp eggs
were hatched in artiﬁcial sea water prepared from 20% sea
salt (Sigma Aldrich, USA). After 48h of incubation (at 25–
29◦C), nauplii (larvae) were collected in 96-well microtiter
plate. Ten larvae were added in each well containing serially
dilutedcrudeplantextracts.After24hofincubation,liveand
dead larvae were counted and LC50 was determined for each
plant extract [34].
2.3. Induction of Diabetes Mellitus. The in vivo study was
conducted on Swiss mice (6–8 weeks), weighing 25±2g,at
an ambient temperature of 25±2◦C and standard food and
water ad libitum. The mice were made diabetic with a single
intraperitonial injection of STZ (3mg/25g of body weight)
in citrate buﬀer, pH 4.5 [35]. This dose produced diabetes
after 7 days with blood glucose level of approximately (200–
250) mg/dL. The entire procedure was carried out as per
stated guidelines of Institutional Animal Ethical Committee.
2.4. Treatment with Plant Extracts. Plant extracts (100μg/
200μL) reconstituted in distilled water with 0.5% DMSO
were injected intraperitonially into the experimental mice
for 21 days. Six animals were kept in each group and the
non-diabetic control and diabetic control received vehicle
(distilled water + 0.5% DMSO) only. After 21 days of the
treatment, the animals were sacriﬁced, organs were removed,
washed with PBS and stored at –20◦Cf o rf u r t h e ru s e .
2.5. Fasting Blood Glucose Level and Weight of Animals.
The fasting glucose level was monitored periodically during
the treatment with the tail prick method using Accucheck
Active Glucometer (Roche Diagnostics GmbH, Germany).
The blood glucose level was measured in milligram per
deciliter. The weights ofthe animals were checkedbeforeand
after treatment.
2.6. Oral Glucose Tolerance Test (OGTT). The oral glucose
tolerance test was performed on overnight fasted normal,
diabetic and treated mice on 21st day of the treatment.
Glucose (2g/kg body weight) was given orally and blood
glucose level was measured at 0, 30, 60, 90, and 120min after
administration of glucose [36].
2.7. Pancreatic and Intestinal Glucosidase Activity. The mice
were sacriﬁced after 21 days of treatment. Pancreatic and
small intestinal tissues were homogenized in 10mM PBS
containing 100mM NaCl and protease inhibitor cocktail.
The homogenates were centrifuged and the supernatant was
used as a source of enzyme. The glucosidase activity was
measured by DNSA method [25].
2.8. G6PD Activity. G6PD activity was checked by Langdon
method [37]. The liver tissue posttreatment was homoge-
nized in 10mM PBS. The change in absorbance of reaction
mixture containing1MTris-chloride buﬀer,25mMglucose-
6-phosphate, 0.2M magnesium chloride, 2mM NADP and
homogenizedtissuewasmeasured at340nmfor10min.One
unit of enzyme activity was deﬁned as the quantity which
catalyzed the reduction of 1μMo fN A D Pp e rm i n u t e[ 13].
2.9. Glycogen Estimation. Glycogen was estimated from liver
and muscle tissues post treatment [38]. The tissues were
homogenized in warm ethanol and centrifuged. The residue
was dried and dissolved in distilled water with perchloric
acid for extraction. This mixture was centrifuged and the
supernatant was estimated for glucose concentration using
phenol sulphuric acid method at 490nm. The amount of
glycogen in the tissue sample was expressed in micrograms
of glucose per milliliter of tissue extract [13].
2.10. Immunohistochemical Analysis. Pancreas from control
diabetic and treated mice were ﬁxed in 4% paraformalde-
hyde.Seven-micrometerthicksections weretakenonarotary
microtome (Thermo Scientiﬁc, Shandonﬁnsse) and used for
immunohistochemical analysis.
2.11. Western Blot Analysis. Equal amount of pancreatic
proteins from control diabetic and treated mice were sep-
arated on 10% SDS polyacrylamide gel and transferred to
nitrocellulose membrane. The human recombinant insulin
was used as positive control. These blots were probed
using guinea pig anti-insulin antibody and the reaction was
visualized using 3,3-diaminobenzidine tetrahydrochloride.
The densitometric analysis was performed on the developed
immunoblot to quantify insulin secretion.
2.12. Plasma Insulin and C-Peptide Analysis. The plasma
insulin and c-peptide were quantitated using mouse insulin
(Mercodia, Sweden) and c-peptide (Yanaihara Institute,
Japan) Elisa kit.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: The data indicates the oral glucose tolerance after the treatment with (a) A. indica and (b) B. spectabilis. The data are indicated as
mean ± SEM (n=6).
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Figure 2: Indicates post-treatment (a) pancreatic, and (b) intestinal glucosidase activity. Data was calculated as mean±SEM (n=6). The
student t-test was used where bars with diﬀerent asterisks (∗∗∗, ∗∗, ∗) shows a signiﬁcant diﬀerence with respect to control where P< .05.
2.13. Statistical Analysis. Data was evaluated using Student’s
paired t-test, one way ANOVA or two-way ANOVA analysis
where appropriate. Groups were considered to be signiﬁ-
cantly diﬀerent if P ≤ .05.
3.Results
3.1. Toxicity Analysis. The toxicity of extracts of A. indica
and B. spectabilis was tested by brine shrimp bioassay. The
average LC50 for A. indica was 7.5mg/mL and B. spectabilis
was 10mg/mL. The total dose of plant extracts given to the
treatment group over a period of 21 days was 2mg/4ml
which is much lower than the LC50 value.
3.2. Fasting Glucose Level and Weight of Animals. The
fasting glucose level was periodically monitored during the
treatment. It was found that chloroform extract of A. indica
and aqueous, methanolic extracts of B. spectabilis showed a
gradual decrease in fasting glucoselevelover the period of21
days. There was a signiﬁcant weight gain comparable to the
control, indicating an increase in muscle mass (Table 1).
3.3. OGTT. The glucose tolerance test was performed to
check the glycemic control of plant extracts after the
treatment. A. indica chloroform extract and B. spectabilis
aqueous, methanolic extracts show good oral glucose toler-
ance (Figure 1).
3.4. Pancreatic and Intestinal Glucosidase Activity. The chlo-
roform and aqueous extract of A. indica showed a signiﬁcant
decrease in the enzyme activity of intestinal glucosidase 51%
and 35%, whereas there was no signiﬁcant reduction in
pancreatic glucosidase. B. spectabilis aqueous extract showed4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of plant extracts on fasting glucose levels and weight of the animals after 21 days of treatment. The data is indicated as
mean±SEM; (n=6).
Group (n=7) Fasting glucose level (mg/dL) Body weight (g)
Diabetic 462±6.22 19±8.66
Control 85 ±6.54 31±7.66
Azadirachta indica (H2O) 187±2.03 21±7.36
Azadirachta indica (MeOH) 140±2.43 27±11.36
Azadirachta indica (ChCl3) 109±5.65 30±4.25
Bougainvillea spectabilis (H2O) 112±5.22 30±5.59
Bougainvillea spectabilis (MeOH) 120±10.26 28±6.98
Bougainvillea spectabilis (ChCl3) 189±4.65 22±10.69
∗∗ ∗∗
∗ ∗∗
∗ ∗∗
0
0.002
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Figure 3: Indicates G6PD restoration activity of plant extract post-
treatment. Data was calculated as mean±SEM (n=6). The student
t-test was used where bars with diﬀerent asterisks (∗∗∗, ∗∗)s h o w sa
signiﬁcantdiﬀerence with respect to control where P< .05.
inhibition with intestinal as well as pancreatic glucosidase of
52% and 48%, respectively (Figure 2).
3.5. G6PD Activity. G6PD indicates the proper glucose
utilization through pentose phosphate pathway in the liver.
The diabetic mice showed a 50% reduction in G6PD activity
in the liver as compared to control after 21 days. There
was a signiﬁcant increase in G6PD activity with A. indica
chloroform, aqueous and B. spectabilis aqueous, methanolic
extracts after 21 days of treatment (Figure 3).
3.6. Liver and Muscle Glycogen Content. Hepatic and skeletal
muscleglycogencontentwasestimatedposttreatment.Inthe
case of diabetic mice, hepatic and muscle glycogen content
was reduced up to 45%. The chloroform extract of A. indica
and aqueous, methanolic extracts of B. spectabilis showed
signiﬁcant increase in liver and muscle glycogen content
(Figure 4).
3.7. Immunohistochemical and Western Blot Analysis. Im-
munohistochemical and western blot analyses were per-
formed to quantify insulin production and β-cell func-
tion post treatment. The chloroform extract of A. indica
and methanolic, aqueous extracts of B. spectabilis showed
increase in functional islets actively producing insulin. Den-
sitometric analysis of western blot resulted in comparable
insulin production as seen in immunohistology. Figure 5(A)
shows representative picture of pancreatic sections and
Figure 5(B) represents immunoblot developed on same
pancreatic tissue protein.
3.8. Plasma Insulin and C-Peptide Analysis. Plasma insulin
and c-peptidewere analyzed tochecktheproperendogenous
insulin secretion from β-cells after treatment with plant
extracts. Insulin and c-peptide were measured in nanograms
per milliliter. Again the chloroform extract of A. indica and
aqueous, methanolic extract of B. spectabilis was able to
normalize the plasma insulin and c-peptide levels (Figure 6).
4.Discussion
A. indica and B. spectabilis are known for their antidiabeto-
genic activities. The earlier studies of these plant extracts
on diabetic rats have shown prevention of diabetes and
oxidative stress [39, 40]. In the present study, we report the
eﬀect of A. indica and B. spectabilis extracts on biochemical
parameters important with respect to diabetes in in vivo
murine model. The eﬀect of plant extracts on metabolic
pathways in STZ-induced diabetic mice was studied in
a duration-dependent manner. STZ is known to produce
hyperglycemia by selective cytotoxic eﬀect on pancreatic β-
cells [41]. A single intraperitonial injection of STZ given to
normoglycemic mice produced hyperglycemia in 7 dayswith
blood glucose level of 200–250mg/dL.
It was observed that treatment of chloroform extract of
A. indica and aqueous, methanolic extracts of B. spectabilis
for 21 days reduced the fasting glucose to signiﬁcantly
normal level, acquiring good glycemic control suggesting
its antihyperglycemic properties (Figure 1). The onset of
antihyperglycemic eﬀect with these extracts was seen within
10 days of treatment, even though maximum and signiﬁcant
reduction was observed only after 15 days. Since we did
not observe any more changes in fasting blood glucose, the
experiment was terminated on 21st day. Body weight, whichEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Indicates glycogen storage of (a) liver and (b) skeletal muscle post-treatment. Data was calculated as mean±SEM (n=6). The
student t-test was used where bars with diﬀerent asterisks (∗∗∗, ∗∗, ∗) shows a signiﬁcant diﬀerence with respect to control where P<.05.
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Figure 5: (A) Immuno-histochemicalanalysis of the mouse pancreas developed with anti-insulin antibody. (a) Normal,(b) Diabetic, (c) A.
indica chloroform extract treated, (d) B. spectabilis aqueous extract treated, (e) B. spectabilis methanolic extract treated with magniﬁcation
of 480x,and (B) immunoblotanalysisofpancreatic protein probed with anti-insulin antibody after treatment with (I) Human recombinant
insulin, (C) control, and (D) diabetic (1) chloroform (2) methanolic (3) aqueous. The data are measured by densitometry in ODU/mm2.6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Indicates the insulin and c-peptide analysis using Elisa kits.
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Figure 7: Diagrammatic representation of glucose metabolic pathways in normaland diabetic case.
is another important parameter in diabetes, also increased
with the treatment of A. indica chloroform extract and B.
spectabilis aqueous extract (Table 1). There was a gradual
increase in the body weight of controls and treated mice
while the diabetic mice continued to lose weight.
In our earlier study, A. indica is reported as a pancreatic,
and B. spectabilis as an intestinal glucosidase inhibitor
[25]. This was also evident in STZ-induced diabetic mice
wherein reduction of pancreatic and intestinal glucosidase
wasobservedaftersupplementingtheseextracts.Glucosidase
are normally present in the pancreas and gut of small
intestine and play an important role in the digestion of
dietary carbohydrates. The inhibitors of α-glucosidase, in
consequence retard the use of dietary carbohydrates to
suppressPPHGindiabetes[42,43]Figure 7.The chloroform
extract of A. indica and methanolic, aqueous extracts of B.
spectabilis retarded the glucosidase activity which helps in
controlling PPHG, resulting in reduction of blood glucose
level (Figure 2). Interestingly, A. indica chloroform extract
has shown 50% reduction in intestinal glucosidase, which
was not seen during an in vitro enzyme inhibition assay.
In an attempt to gain an insight into the underly-
ing biochemical mechanisms involved in antidiabetogenic
activities of plant extracts, G6PD activity was estimated.Evidence-Based Complementary and Alternative Medicine 7
G6PD is the key enzyme in pentose phosphate pathway
which helps in maintaining the normal blood glucose levels
[44]( Figure 7). In STZ-induced diabetic murine model,
G6PD activity in liver reduces signiﬁcantly which obstructs
glucose utilization and leads to hyperglycemia [45]. The
treatment with chloroform extract of A. indica and aqueous,
methanolic extracts of B. spectabilis resulted in a signiﬁcant
restoration of the enzyme activity in treated mice which
couldbe duetoincrease in insulin productionasthisenzyme
activity depends on insulin (Figure 3).
Insulin is the main regulator of glycogen synthesis in
hepatic and skeletal muscles(Figure 7). Itpromotesglycogen
synthesis by stimulating glucose uptake and activating the
key enzyme, glycogen synthase [30, 46]. There are reports
of impairment of hepatic and skeletal glycogen synthesis
in diabetic rats [47–49]. We observed 50% reduction in
both muscle and hepatic glycogen content in diabetic mice
which may be due to lack of insulin in the diabetic state.
The supplementation of A. indica chloroform extract and
B. spectabilis aqueous and methanolic extracts has shown a
signiﬁcant increase in glycogen level in diabetic mice which
may be due to the reactivation of glycogen synthase systems
(Figure 4). This indicates that plant extracts have a direct
eﬀect on muscle and liver glucose metabolism which helps
in prevention of loss of muscle mass in diabetes.
In the present study, we further performed immunohis-
tochemical analysis of pancreatic sections to check insulin
secretion and islet regeneration properties of these plant
extracts. It was found that A. indica chloroform and B.
spectabilis aqueous, methanolic extracts showed signiﬁcant
regeneration property of functional β-cells (Figure 5(A)).
The immunoblot and densitometric analysis on pancreatic
protein further supported the histological ﬁnding showing
increase in insulin levels with these extracts (Figure 5(B)).
It is known that there is decrease in c-peptide levels during
diabetes because of autoimmune destruction of β-cells. In
our study, we measured insulin and c-peptide levels from
treated animals to determine how much of their own natural
insulin is being produced. We observed normalization in
plasma insulin and c-peptide levels which further corrobo-
rated the formation of functional islets and insulin release
with A. indica chloroform extract and B. spectabilis aqueous
extracts treatment. Earlier, Gymnema sylvestry was reported
tohavepancreatic islet regeneration property within diabetic
mice [50]. This further supports the data that A. indica
chloroform extract and B. spectabilis aqueous extracts have
islet regenerative and insulin-producing property. These
extracts stimulate the β-cells to secrete insulin in STZ-
induced diabetic mice, resulting in the improvement of
carbohydrate metabolism towards the re-establishment of
normal blood glucose level.
This study is signiﬁcant as it covers various important
biochemical and metabolic aspects responsible for the pro-
gression of diabetes. These plant extracts have deﬁnitely
shown multiple biological targets; however, at this stage it
is diﬃcult to predict whether all the components act inde-
pendently or in synergetic manner because active principles
or biomolecules are responsible for their antidiabetogenic
eﬀect, which is required to be identiﬁed. One common
reason emerging from this study is the eﬀect of the extracts
onisletsregenerationandinsulinproductionwhichcanindi-
rectly modulate all otherbiochemical parameters. Due to the
interesting ﬁnding of possible islet regenerative/protective
property and low toxicity, these plant extracts can be
evaluated further for their introduction as neutraceutical for
the treatment of diabetes.
5.Conclusion
The data suggest that A. indica chloroform extract and B.
spectabilis aqueous, methanolic extracts exhibit islet regen-
eration/protection properties and therefore have beneﬁcial
eﬀects in diabetes mellitus that holds the hope of new
generation of antidiabetic drugs.
Funding
Senior Research Fellowship from Council of Scientiﬁc and
Industrial Research (CSIR, Government of India) (to M.B.);
ﬁnancial support from CSIR, India.
Acknowledgment
The authors acknowledge Department of Zoology, Univer-
sity of Pune for providing animal house facilities.
References
[1] G.Klein,J.Kim,K.Himmeldirk,Y.Cao,andX.Chen,“Antidi-
abetes and anti-obesity activity of Lagerstroemia speciosa,”
Evidence-Based Complementary and Alternative Medicine,v o l .
4, no. 4, pp. 401–407, 2007.
[2] R.R.HolmanandR.C.Turner,“Oralagentsandinsulininthe
treatment of NIDDM,” in Textbook of Diabetes,J .P i c k u pa n d
G. Wiliams,Eds., pp. 407–69, Blackwell, Oxford, UK, 1991.
[ 3 ]S .K .S i n g h ,P .K .R a i ,D .J a i s w a l ,a n dG .W a t a l ,“ E v i d e n c e -
based critical evaluation of glycaemic potential of Cynodon
dactylon,” Evidence-Based Complementary and Alternative
Medicine, vol. 5, no. 4, pp. 415–420, 2008.
[4] M. S. Valiathan, “Healing plants,” Current Science, vol. 75, no.
11, pp. 1122–1127, 1998.
[5] American Diabetes Association, “Standards of medical care in
diabetes,” Diabetes Care, vol. 30, pp. 4–41, 2007.
[6] S. VenkateswaranandL. Pari,“Eﬀects of Coccinia indica leaves
on antioxidant status in streptotocin-induced diabetic rats,”
Journal of Ethnopharmacology, vol. 84, pp. 163–168, 2003.
[7] S. Samane, J. No¨ e l ,Z .C h a r r o u f ,H .A m a r o u c h ,a n dP .S .
Haddad, “Insulin-sensitizing and anti-proliferative eﬀects of
Argania spinosa seed extracts,” Evidence-Based Complemen-
tary and Alternative Medicine, vol. 3, no. 3, pp. 317–327, 2006.
[8] J.Z.LuoandL.Luo,“ Americanginsengstimulatesinsulinpro-
duction and prevents apoptosis through regulation of uncou-
pling protein-2 in cultured β cells,” Evidence-Based Comple-
mentary and Alternative Medicine, vol. 3, pp. 365–372, 2006.
[9] I. S. Punitha, K. Rajendran, A. Shirwaikar, and A. Shirwaikar,
“Alcoholic stem extract of Coscinium fenestratum regulates
carbohydrate metabolism and improves antioxidant status in
streptozotocin-nicotinamide induced diabetic rats,” Evidence-
Based Complementary and Alternative Medicine,v o l .2 ,p p .
375–381, 2005.8 Evidence-Based Complementary and Alternative Medicine
[ 1 0 ]B .Q i n ,M .N a g a s a k i ,M .R e n ,G .B a j o t t o ,Y .O s h i d a ,a n dY .
Sato, “Goshajinki-gan (a herbal complex) corrects abnormal
insulin signaling,” Evidence-Based Complementary and
Alternative Medicine, vol. 1, pp. 269–276, 2004.
[11] P. S. Haddad, G. A. Azar, S. Groom, and M. Boivin, “Natural
health products, modulation of immune function and pre-
vention of chronic diseases,” Evidence-Based Complementary
and Alternative Medicine, vol. 2, no. 4, pp. 513–520, 2005.
[12] J. H. Hsu, Y. C. Wu, S. S. Liou, I. M. Liu, L. W. Huang, and
J. T. Cheng, “Mediation of endogenous beta-endorphin by
tetrandrine to lowerplasmaglucosein streptozotocin-induced
diabetic rats,” Evidence-Based Complementary and Alternative
Medicine, vol. 1, pp. 193–201, 2004.
[13] R. Maiti, D. Jana, U. K. Das, and D. Ghosh, “Antidiabetic
eﬀect of aqueous extract of seed of Tamarindus indica
in streptozotocin-induced diabetic rats,” Journal of
Ethnopharmacology, vol. 92, no. 1, pp. 85–91, 2004.
[14] O. Ladeji, I. Omekarah, and M. Solomon, “Hypoglycemic
properties of aqueous bark extract of Ceiba pentandra
in streptozotocin-induced diabetic rats,” Journal of
Ethnopharmacology, vol. 84, no. 2-3, pp. 139–142, 2003.
[ 1 5 ] P .S .P r i n c e ,V .P .M e n o n ,a n dL .P a r i ,“ H y p o g l y c a e m i ca c t i v i t y
of Syzyginium cumini seeds: eﬀect on lipid peroxidation in
alloxon diabetic rats,” Journal of Ethnopharmacology, vol. 61,
pp. 1–7, 1998.
[16] P. Khosla, S. Bhanwara, J. Singh, S. Seth, and R. K. Srivastava,
“A study of hyperglycemia eﬀects of A. indica (Neem) in
normal and alloxan diabetic rabbits,” Indian Journal of
Physiology & Pharmacology, vol. 44, pp. 69–74, 2000.
[17] K. N. Bopana, J. Kannan, S. Gadgil, R. Balaram, and S. P.
Rathod, “Antidiabetic and antihyperlipidaemic eﬀects of
neem seed kernel powder on alloxan diabetic rabbits,” Indian
Journal of Pharmacology, vol. 29, pp. 162–167, 1997.
[18] National Research Council, Neem: A Tree for Solving Global
Problems, National Academy Press, Washington, DC, USA,
1992.
[19] T. R. Govindachari, G. Sandhya, and S. P. Ganeshraj, “Simple
method for the isolation of azadirachtin by preparative
high-performance liquid chromatography,” Journal of
Chromatography, vol. 513, pp. 389–391, 1990.
[20] I. Ara, B. S. Siddiqui, S. Faizi, and S. Siddiqui, “Diterpenoids
from the stem bark of Azadirachta indica,” Phytochemistry,
vol. 28, no. 4, pp. 1177–1180, 1989.
[21] S. P. Basak and D. P. Chakroborty, “Chemical investigation of
Azadirachta indica leaf (M. azadirachta),”Journal of the Indian
Chemical Society, vol. 45, pp. 466–467, 1969.
[22] J.O.Adebayo, A.A.Adesokan,L.A.Olatunji,D.O.Buoro,and
A. O. Soladoye, “Eﬀect of ethanolic extract of Bougainvillea
spectabilis leaves on haematological and serum lipid variables
in rats,” Biochemistry, vol. 17, pp. 45–50, 2005.
[23] C. R. Narayanan, D. D. Joshi, A. M. Mujumdar, and V. V.
Dhekne, “Pinitol, a new antidiabetic compound from the
leaves ofBougainvillea spectabilis,” Current Science,vol. 56, pp.
139–141, 1987.
[24] C. R. Narayanan, D. D. Joshi, and A. M. Mujumdar,
“Hypoglycaemic action of Bougainvillea spectabilis leaves,”
Current Science, vol. 53, pp. 579–581, 1984.
[25] M. Bhat, S. S. Zinjarde, S. Y. Bhargava, A. Ravikumar, and
B. N. Joshi, “Antidiabetic Indian plants: a good source of
potent amylase inhibitors,” Evidence-Based Complementary
and Alternative Medicine. In press.
[26] M. Kanitkar and R. Bhonde, “Existence of islet regenerating
factors within the pancreas,” The Review of Diabetic Studies,
vol. 1, pp. 185–192, 2004.
[27] M. Banerjee and R. R. Bhonde, “Islet generation from intra
islet precursor cells of diabetic pancreas: in vitro studies
depicting in vivo diﬀerentiation,” Journal of the Pancreas,v o l .
4, no. 4, pp. 137–145, 2003.
[28] A. M. Gray and P. R. Flatt, “Pancreatic and extra-pancreatic
eﬀects of the traditional anti-diabetic plant, Medicago sativa
(lucerne),” British Journal of Nutrition, vol. 78, no. 2, pp.
325–334, 1997.
[29] G. Martini and M. V. Ursini, “A new lease of life for an old
enzyme,” BioEssays, vol. 18, no. 8, pp. 631–637, 1996.
[30] J. C. Lawrence Jr. and P. J. Roach, “New insights into the role
and mechanism of glycogen synthase activation by insulin,”
Diabetes, vol. 46, no. 4, pp. 541–547, 1997.
[31] R. H. Rury, C. T. Robert, and A. C. Carole, “A randomized
double-blind trial of acarbose in type 2 diabetes shows
improved glycaemic control over 3 years (U.K. Prospective
Diabetes Study 44),” Diabetes Care, vol.22, pp. 960–964,1999.
[32] N. Saito, H. Sakai, S. Suzuki, H. Sekihara, and Y. Yajima,
“Eﬀect of an alpha-glucosidase inhibitor (voglibose), in
combination with sulphonylureas, on glycaemic control in
type 2 diabetes patients,” Journal of International Medical
Research, vol. 26, pp. 219–232, 1998.
[ 3 3 ] B .N .M e y e r ,N .R .F e r r i g n i ,J .E .P u t n a m ,L .B .J a c o b s e n ,D .E .
N i c h o l s ,a n dL .L .M c L a u g h l i n ,“ B r i n es h r i m p :ac o n v e n i e n t
general bioassay for active plant constituents,” Planta Medica,
vol. 45, pp. 31–34, 1982.
[34] L. Y. Latha, S. Sasidharan, Z. Zuraini et al., “Antimicrobial
activities and toxicity of crude extract of the Psophocarpus
tetragonolobus pods,” African Journal of Traditional, Com-
plementary and Alternative Medicines, vol. 4, no. 1, pp. 59–63,
2007.
[35] T. Szkudelski, “The mechanism of alloxan and streptozotocin
action in beta cells of the rat pancreas,” Physiological Research,
vol. 50, no. 6, pp. 537–546, 2001.
[36] M. Vessal, M. Hemmati, and M. Vasei, “Antidiabetic eﬀects of
quercetin in streptozotocin-induced diabetic rats,” Compara-
tive Biochemistry and Physiology C, vol. 3, pp. 357–364, 2003.
[37] R. G. Langdon, “Glucose-6-phosphate dehydrogenase from
erythrocytes,” Methods in Enzymology, vol. 9, pp. 126–131,
1966.
[38] S. Sadasivam and A. Manickam, “Carbohydrates,” in Methods
in Biochemistry, pp. 11–12, New Age International, New
Delhi, India, 1996.
[39] A. Chandra, A. A. Mahdi, R. K. Singh, F. Mahdi, and R.
Chander, “Eﬀect of Indian herbal hypoglycaemic agents on
antioxidant capacity and trace elements content in diabetic
rats,” Journal of Medicinal Food, vol. 11, pp. 506–512, 2008.
[40] A. Chandra, A. A. Mahdi, S. Ahmad, and R. K. Singh, “Indian
herbs result in hypoglycemic responses in streptozotocin-
induced diabetic rats,” Nutrition Research,v o l .2 7 ,n o .3 ,p p .
161–168, 2007.
[41] G. Kavalali, H. Tuncel, S. G¨ oksel, and H. H. Hatemi,
“Hypoglycemic activity of Urtica pilulifera in streptozotocin-
diabetic rats,” Journal of Ethnopharmacology, vol. 84, no. 2-3,
pp. 241–245, 2002.
[42] H. Matsuura, C. Asakawa, M. Kurimoto, and J. Mizutani,
“α-glucosidase inhibitorfrom the seeds ofbalsampear (Mom-
ordica charantia)a n dt h ef r u i tb o d i e so fGrifola frondosa,” Bio-
science, Biotechnology and Biochemistry,v o l .6 6 ,n o .7 ,p p .
1576–1578, 2002.
[43] A. D. Mooradian and J. E. Thurman, “Drug therapy of
postprandial hyperglycaemia,” Drugs,v o l .5 7 ,n o .1 ,p p .
19–29, 1999.Evidence-Based Complementary and Alternative Medicine 9
[44] P. A. Mayes, “The pentose phosphate pathway and other
pathway of hexose metabolism,” in Herper’s Biochemistry,R .
K. Murray, D. K. Granner, and V. W. Mayes, Eds., pp. 219–37,
McGraw-Hill, New York, NY, USA, 2000.
[45] N. H. Ugochukwu and N. E. Babady, “Antihyperglycaemic
eﬀect of aqueous and ethanolic extract of Gongronema
latifolium leaves on glucose and glycogen metabolism in liver
of normal and streptozotocin-induced diabetic rats,” Life
Sciences, vol. 73, pp. 1925–1938, 2003.
[46] A. C. Borthwick, A. M. Wells, J. J. Rochford, S. J. Hurel,
D. M. Turnbull, and S. J. Yeaman, “Inhibition of glycogen
synthase kinase-3 by insulin in cultured human skeletal
muscle myoblasts,” Biochemical and Biophysical Research
Communications, vol. 210, no. 3, pp. 738–745, 1995.
[47] J. K. Grover, S. Yadav, and V. Vats, “Medicinal plants of India
with anti-diabetic potential,” Journal of Ethnopharmacology,
vol. 81, no. 1, pp. 81–100, 2002.
[48] X. Huang, A. Vaag, M. Hanson, J. Weng, and L. Goop,
“Impaired insulin stimulated expression of the glycogen
synthase gene in skeletal muscle of type 2 diabetic patients
is acquired rather than inherited,” Journal of Clinical
Endocrinology & Metabolism, vol. 85, pp. 1584–1590, 2000.
[49] P. D. Whitton and D. A. Hems, “Glycogen synthesis in the
perfused liver of streptozotocin diabetic rats,” Biochemical
Journal, vol. 150, no. 2, pp. 153–165, 1975.
[50] E. R. Shanmugasundaram, K. L. Gopinath, S. K. Radha,
and V. M. Rajendran, “Possible regeneration of the islets of
Langerhans in streptozotocin-diabetic rats given Gymnema
sylvestre leaf extracts,” Journal of Ethnopharmacology, vol. 30,
pp. 265–279, 1990.